945 F.3d 1184
Fed. Cir.2019Background
- Persion (formerly Pernix) owns U.S. Patents 9,265,760 and 9,339,499 directed to methods of treating pain in patients with mild or moderate hepatic impairment using extended‑release hydrocodone bitartrate as the only active ingredient. Claims include (a) non‑adjustment claims (no dose reduction for impaired patients) and (b) pharmacokinetic claims (specific AUC and Cmax limits relative to unimpaired subjects).
- Devane (published 2006) discloses multiparticulate modified‑release compositions and expressly identifies a formulation identical to Zohydro ER (the claimed extended‑release hydrocodone‑only product) and reports in vivo data in healthy subjects.
- Jain (published 2010) discloses an extended‑release hydrocodone/acetaminophen combination (Vicodin CR) and reports clinical data showing hydrocodone pharmacokinetics were similar in normal and mildly/moderately hepatically impaired subjects.
- Labels for immediate‑release hydrocodone/acetaminophen products (Vicodin, Lortab) did not require dose adjustments for mild/moderate hepatic impairment, and FDA practice allowed some reliance on combination product data in NDA submissions.
- District court found asserted claims invalid as obvious over Devane in view of Jain, the state of the art, and product labels, concluding the pharmacokinetic limitations were inherent in the Devane/Zohydro formulation; it also found lack of written description but the Federal Circuit affirmed based on obviousness and did not reach the written description ruling.
Issues
| Issue | Plaintiff's Argument (Persion) | Defendant's Argument (Alvogen) | Held |
|---|---|---|---|
| Whether pharmacokinetic limitations can be supplied by inherency in the prior art | Inherency cannot supply pharmacokinetic limits because Devane does not teach administration to hepatically impaired patients | Inherency applies because Devane combined with Jain and labels would lead a skilled artisan to administer Devane formulation to impaired patients and the PK values are necessarily present | Court: Inherency may supply the PK limitations; district court did not err |
| Whether relying on PK data from combination products, immediate‑release products, or unimpaired patients was improper | Such data are irrelevant; cannot predict dosing of a hydrocodone‑only ER in hepatically impaired patients | Those data were relevant to a person of ordinary skill; acetaminophen toxicity provides motive to remove it and experts showed hydrocodone PK are similar across formulations | Court: No clear error in using that evidence to motivate and support a reasonable expectation of success |
| Whether objective indicia (unexpected results, long‑felt need, failure of others) were improperly considered after finding obviousness | District court prematurely found obviousness without properly weighing objective indicia | District court considered objective indicia in the totality of evidence and gave them appropriate weight | Court: District court properly considered and weighed objective indicia; no reversible error |
| Whether district court’s obviousness findings conflict with its written description findings | Findings are inconsistent because obviousness relied on prior art guidance while written description said no guidance existed | District court distinguished guidance limited to the single Devane embodiment from the lack of guidance for broadly claimed formulations | Court: No inconsistency; findings are compatible and do not require reversal |
Key Cases Cited
- KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398 (Sup. Ct. 2007) (framework for obviousness analysis)
- Santarus, Inc. v. Par Pharm., Inc., 694 F.3d 1344 (Fed. Cir. 2012) (inherent properties do not impart patentable weight when present in prior art formulation)
- PAR Pharm., Inc. v. TWI Pharm., Inc., 773 F.3d 1186 (Fed. Cir. 2014) (inherency in obviousness analysis and its limits)
- In re Oelrich, 666 F.2d 578 (C.C.P.A. 1981) (inherency requires natural/result necessarily present, not mere possibility)
- In re Kao, 639 F.3d 1057 (Fed. Cir. 2011) (inherent pharmacokinetic property added nothing patentable)
- In re Kubin, 561 F.3d 1351 (Fed. Cir. 2009) (inherency may supply missing limitation when necessarily present)
- Gen. Elec. Co. v. Jewel Incandescent Lamp Co., 326 U.S. 242 (1945) (discovery of inherent properties is not invention)
- Zenith Radio Corp. v. Hazeltine Research, Inc., 395 U.S. 100 (1969) (clear‑error standard in bench trial review)
- In re Cyclobenzaprine Hydrochloride Extended‑Release Capsule Patent Litig., 676 F.3d 1063 (Fed. Cir. 2012) (proper consideration of objective indicia)